Abstract: Generating PKI credentials for authenticating a networking appliance attempting to attach to a network includes: receiving a certificate signing request (CSR) from the networking appliance, wherein the CSR comprises credential data associated with an identity of the networking appliance; generating an appliance certificate based on the credential data and a certificate authority (CA) certificate associated with the computer; and returning the appliance certificate to the networking appliance.

Abstract: Authenticating a networking appliance attempting to attach to a network includes receiving a request from the networking appliance to attach to the network, wherein the request comprises credential data associated with the networking appliance and a certificate authority (CA) certificate associated with the computer; receiving at least one value associated with an identity of the networking appliance; and authenticating the identity of the networking appliance based on both a) the at least one value associated with the identity of the networking appliance; and b) the appliance certificate.

Abstract: Authenticating a networking appliance attempting to attach to a network includes receiving at least one value associated with an identity of the networking appliance; receiving a certificate signing request (CSR) from the networking appliance, wherein the CSR comprises credential data associated with the identity of the networking appliance; and generating an appliance certificate based on the credential data and a certificate authority (CA) certificate associated with the computer. The method also includes returning the appliance certificate to the networking appliance; receiving a request from the networking appliance to attach to the network; and authenticating the identity of the networking appliance based on both a) the at least one value associated with the identity of the networking appliance; and b) the appliance certificate.

Abstract: Generating PKI credentials for authenticating a networking appliance attempting to attach to a network includes: receiving a certificate signing request (CSR) from the networking appliance, wherein the CSR comprises credential data associated with an identity of the networking appliance; generating an appliance certificate based on the credential data and a certificate authority (CA) certificate associated with the computer; and returning the appliance certificate to the networking appliance.

Abstract: Authenticating a networking appliance attempting to attach to a network includes receiving at least one value associated with an identity of the networking appliance; receiving a certificate signing request (CSR) from the networking appliance, wherein the CSR comprises credential data associated with the identity of the networking appliance; and generating an appliance certificate based on the credential data and a certificate authority (CA) certificate associated with the computer. The method also includes returning the appliance certificate to the networking appliance; receiving a request from the networking appliance to attach to the network; and authenticating the identity of the networking appliance based on both a) the at least one value associated with the identity of the networking appliance; and b) the appliance certificate.

Abstract: Authenticating a networking appliance attempting to attach to a network includes receiving a request from the networking appliance to attach to the network, wherein the request comprises credential data associated with the networking appliance and a certificate authority (CA) certificate associated with the computer; receiving at least one value associated with an identity of the networking appliance; and authenticating the identity of the networking appliance based on both a) the at least one value associated with the identity of the networking appliance; and b) the appliance certificate.

Abstract: This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: A toll charging system responsive to a traveling length and the method for operating the same are disclosed. The system comprises a plurality of control path units, a user mobile communication unit, at least one mobile communication unit, and at least one financial unit. The method comprises the step of identifying a vehicle by a vehicle identification devices in outlet and control path unit. Then a signal emitting device transfers vehicle and location information to a mobile communication base unit. Then, the mobile communication device transfers a message of user's financial account and vehicle information to a mobile communication base unit. The signal emitting device transfers information to the mobile communication base unit. The mobile communication device again transfers a message of user's financial account and vehicle information. Then, a central processing unit calculates a toll responsive to received information; and paying the toll to a financial unit.

Abstract: This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.